Surgi Plast Under the Microscope: What Pakistan’s Regulatory Records Reveal About Its Medical Devices

Surgi Plast is not simply another name in Pakistan’s medical-supplies market. Official records connect the manufacturer with disposable syringes, auto-disable syringes, insulin syringes and intravenous products produced from its facility in Gadoon Amazai, Swabi, Khyber Pakhtunkhwa.

That regulatory footprint became particularly significant in May and June 2026, when Pakistan’s Drug Regulatory Authority, or DRAP, published safety alerts involving specific batches of Clinic Auto Disable Syringe 3ml/cc associated with the manufacturer. Laboratory findings focused on failure of the feature intended to prevent a syringe from being used again.

The distinction is critical: the official notices identify particular products and batches, not every medical device produced by Surgi Plast.

BLUF: Surgi Plast is a Pakistan-based medical-device manufacturer registered with DRAP for syringe and IV-set manufacturing. In 2026, specific batches of its Clinic 3ml auto-disable syringes were declared substandard after testing identified failure of the reuse-prevention mechanism; the available notices do not establish a company-wide recall.

Clinic Is More Than a Marketing Name—It Appears in DRAP Registrations

The Clinic brand has a documented regulatory relationship with Surgi Plast.

One important registration is MDMR-000115, issued on March 31, 2021. DRAP records identify it as covering Clinic Auto Disable Syringes in 2ml, 3ml and 5ml sizes manufactured by Surgi Plast.

Later registration records add further products.

Product	DRAP reference	Recorded date
Clinic Auto Disable Syringes, 2ml/3ml/5ml	MDMR-000115	March 31, 2021
Clinic Disposable Syringe, 30/50/60ml with specified needles	MDMR-000307	December 20, 2023
Clinic Insulin Syringe, 1cc	MDMR-000308	December 20, 2023
Clinic Blood Transfusion Set	MDMR-000487	March 3, 2025

The 2023 syringe and insulin-syringe registrations are listed in DRAP’s local medical-device database, while later regulatory records include the blood-transfusion set.

This matters for buyers because product registration should be checked at the device level, not inferred merely because a manufacturer is licensed.

Why One Small Auto-Disable Mechanism Became the Central 2026 Issue

An auto-disable syringe is designed to prevent normal reuse after its intended injection.

That feature is not cosmetic.

The World Health Organization strongly recommends auto-disable syringes for vaccine administration because their reuse-prevention mechanism reduces the possibility of person-to-person transmission associated with syringe reuse. WHO identifies ISO 7886-3 as the relevant performance standard for auto-disable syringes used for fixed-dose immunization.

For an auto-disable syringe, the safety mechanism is part of the device’s essential function. If that mechanism does not operate as required, the problem affects the very feature intended to prevent reuse.

CDC guidance similarly states that healthcare providers should never reuse a needle or syringe on more than one patient because unsafe reuse can spread disease.

This explains why an apparently technical laboratory failure can produce a regulatory recall.

May 22 and June 8: The Surgi Plast Batch Numbers That Matter

DRAP published a recall alert on May 22, 2026 after the Central Drug Laboratory in Karachi declared several auto-disable syringe samples substandard.

Among the products identified were Clinic Auto Disable Syringe 3ml/cc, registration MDMR-000115, manufactured by Surgi Plast Industries in Gadoon Amazai, Swabi.

The Surgi Plast batches identified were:

• 3-01C-26
• 3-01B-26

The regulatory issue concerned the syringe’s auto-disable or reuse-prevention performance.

A further DRAP alert dated June 8, 2026 again identified Clinic Auto Disable Syringe 3ml, including batch 3-01B-26, as substandard on the basis of failure of the Self-Destructive Performance / Auto-Disability Test.

The 2026 sequence

March 31, 2021: Clinic Auto Disable Syringes in 2ml, 3ml and 5ml appear under registration MDMR-000115.

May 22, 2026: DRAP publishes a recall alert covering Clinic 3ml/cc batches 3-01C-26 and 3-01B-26.

June 8, 2026: Another official alert identifies 3-01B-26 and specifies failure of the reuse-prevention feature.

September 7, 2026: The available official evidence reviewed for this article supports a batch-specific safety issue, rather than the claim that all Surgi Plast products have been recalled.

That final distinction should not be lost when the story is reduced to a headline.

What Buyers Should Check Before Treating Surgi Plast as One Uniform Product Line

Healthcare procurement works poorly when a manufacturer is judged only by its name.

The better approach is to identify the exact device.

For Surgi Plast products, buyers, pharmacists and healthcare institutions should compare at least:

1. Exact product name
2. Medical-device registration number
3. Batch or lot number
4. Capacity, such as 3ml or 5ml
5. Needle specification where applicable
6. Sterility and expiry information
7. Current DRAP recall or safety alerts
8. Supplier and distribution documentation

A batch not named in one recall should not automatically be treated as officially cleared forever. Regulatory information can change, and physical packaging, storage conditions or later notices may affect a purchasing decision.

Conversely, a recall involving one batch should not be presented as proof that unrelated batches or completely different Surgi Plast products failed testing.

For medical-device reporting, specificity is safer than reputation-based assumptions.

Surgi Plast Questions People Are Asking

What is Surgi Plast?

Surgi Plast is a Pakistani medical-device manufacturer operating from the Gadoon Amazai Industrial Estate in Swabi, Khyber Pakhtunkhwa. DRAP establishment records list syringe and IV-set manufacturing sections at the facility under establishment reference ELM-0030.

What products does Surgi Plast manufacture?

Surgi Plast is officially associated with Clinic-branded medical devices, including auto-disable syringes, larger disposable syringes, insulin syringes and a blood-transfusion set. Individual products have separate DRAP registration references, so the regulatory status of one item should not automatically be applied to another.

Were Surgi Plast syringes recalled in 2026?

Yes. Specific Clinic Auto Disable Syringe 3ml/cc batches were included in DRAP recall alerts in 2026. The May 22 notice included batches 3-01C-26 and 3-01B-26, while a June alert again identified 3-01B-26.

Why were the Clinic auto-disable syringes declared substandard?

The regulatory finding involved failure of the self-destructive performance or auto-disability test, which assesses the mechanism designed to prevent syringe reuse. That function is particularly important because preventing reuse is the defining safety purpose of an auto-disable syringe.

Were all Surgi Plast products recalled?

No company-wide recall is established by the official notices reviewed here. DRAP identified particular Clinic auto-disable syringe batches. Those notices should not be expanded into a claim that every syringe, IV product or other device manufactured by Surgi Plast was defective.

How can someone check a Surgi Plast syringe?

Check the product name, DRAP registration number and batch number printed on the packaging against current DRAP recall information. If a device matches an active recall notice, healthcare professionals, distributors and institutions should follow the regulator’s instructions rather than relying on general online product descriptions.

The Most Important Detail Is Printed on the Box

Surgi Plast has a verifiable place in Pakistan’s regulated medical-device sector. Its Gadoon Amazai manufacturing operation, establishment reference and multiple Clinic product registrations can all be traced through public regulatory documentation.

The 2026 story, however, demonstrates why medical-device research must go deeper than identifying a manufacturer.

Two syringes carrying the same brand name can come from different batches. One regulatory finding does not automatically condemn an entire manufacturer, but neither should a recognised brand override an official safety warning.

For Surgi Plast, the most useful question is therefore not simply “Is this brand safe?”

It is: What exact product, registration number and batch am I looking at—and what does the latest regulator record say about it?

Businessbiohub.com

Editorial Disclaimer

This article is an independent informational review based on regulatory and other publicly available records checked through September 7, 2026. It does not provide medical advice, certify any product as safe, or replace current DRAP instructions. Product registrations, recalls and manufacturing approvals can change; buyers and healthcare professionals should verify the latest official record and exact batch before use or procurement.